Abstract:BACKGROUND:Recent studies show that mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson's disease (PD). The molecular mechanism underlying the pathogenic role of LRRK2 mutations in PD remains unknown.METHODOLOGY/PRINCIPAL FINDINGS:Using affinity purification and mass spectrometric analysis, we investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain. We identified multiple phosphorylation sites at N-terminus of LRRK2 including S910, S912, S935 and S973. Focusing on the high stoichiometry S935 phosphorylation site, we developed an anti-pS935 specific antibody and showed that LRRK2 is constitutively phosphorylated at S935 in various tissues (including brain) and at different ages in mice. We find that 14-3-3 proteins (especially isoforms γ and η) bind LRRK2 and this binding depends on phosphorylation of S935. The binding of 14-3-3, with little effect on dimer formation of LRRK2, confers protection of the phosphorylation status of S935. Furthermore, we show that protein kinase A (PKA), but not LRRK2 kinase itself, can cause the phosphorylation of LRRK2 at S935 in vitro and in cell culture, suggesting that PKA is a potential upstream kinase that regulates LRRK2 function. Finally, our study indicates that the common PD-related mutations of LRRK2, R1441G, Y1699C and G2019S, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.CONCLUSIONS/SIGNIFICANCE:LRRK2 is extensively phosphorylated in vivo, and the phosphorylation of specific sites (e.g. S935) determines 14-3-3 binding of LRRK2. We propose that 14-3-3 is an important regulator of LRRK2-mediated cellular functions. Our study suggests that PKA, a cAMP-dependent kinase involved in regulating dopamine physiology, is a potential upstream kinase that phosphorylates LRRK2 at S935. Furthermore, the reduction of phosphorylation/14-3-3 binding of LRRK2 due to the common familial PD-related mutations provides novel insight into the pathogenic mechanism of LRRK2-linked PD.

Membrane remodeling properties of the Parkinson's disease protein LRRK2

Structural Model of the Dimeric Parkinson'S Protein Lrrk2 Reveals A Compact Architecture Involving Distant Interdomain Contacts

LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis

“LRRK2: Autophagy and Lysosomal Activity”

LRRK2 Mediated Rab8a Phosphorylation Promotes Lipid Storage

How Parkinson's Disease-Related Mutations Disrupt the Dimerization of WD40 Domain in LRRK2: a Comparative Molecular Dynamics Simulation Study

Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2

Phosphorylation-dependent 14-3-3 Binding to LRRK2 is Impaired by Common Mutations of Familial Parkinson's Disease.

Leucine-Rich Repeat Kinases

LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1.

Leucine-rich Repeat Kinase 2 (LRRK2) Interacts with Parkin, and Mutant LRRK2 Induces Neuronal Degeneration

Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.

LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner

Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2

LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice

Roles of the Drosophila Lrrk2 Homolog in Rab7-Dependent Lysosomal Positioning

Leucine-Rich Repeat Kinase 2 Binds to Neuronal Vesicles Through Protein Interactions Mediated by Its C-Terminal WD40 Domain

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival

Electron Microscopy Structure of Dimeric Lrrk2 Reveals A Structural and Regulatory Role of the Cor Domain

Intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase dependent mechanism

Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism